Sort
10,766 grants matching “checkpoint inhibitor”
Dual action immunostimulatory nanoparticles for treatment of aggressive cancers
$540,823Efstathios Karathanasis · Case Western Reserve University · R01 · FY2025 · CA
Pan-Cancer characterization of 3âUTR somatic mutations controlling tumor immune evasion
$540,818Ioannis Vlachos · Beth Israel Deaconess Medical Center · R01 · FY2024 · CA
Novel combined immunotherapeutic strategies for glioma: using pet dogs as a large animal spontaneous model
$540,797Grace Elizabeth Pluhar · University Of Minnesota · U01 · FY2020 · CA
Novel combined immunotherapeutic strategies for glioma: using pet dogs as a large animal spontaneous model
$540,797Grace Elizabeth Pluhar · University Of Minnesota · U01 · FY2021 · CA
Defining the role of NF1 and SPRED1 loss in melanoma
$540,515Iwei Yeh · University Of California, San Francisco · R37 · FY2022 · CA
Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells
$540,493Eric T Ahrens · University Of California, San Diego · R01 · FY2017 · CA
PAG is a novel target in immunotherapy
$540,458Adam Mor · Columbia University Health Sciences · R01 · FY2023 · AI
Mechanistic maps of adaptive responses to therapeutic stress to optimize combination therapies.
$540,450Gordon B. Mills · Oregon Health & Science University · U01 · FY2021 · CA
Preserving CTLA-4 immune checkpoint for safer and more effective cancer immunotherapy
$540,369Lishan Su · University Of Maryland Baltimore · R01 · FY2020 · AI
Role of bacterial-derived small molecules in immunotherapy
$540,288Christian Jobin · University Of Florida · R01 · FY2025 · CA
Integration of Actin Dynamics and Adhesion in Cell Migration
$540,240Clare Michal Waterman · National Heart, Lung, And Blood Institute · ZIA · FY2021 · HL
Developing new therapeutic strategies for brain metastasis
$540,115Eva Hernando · New York University School Of Medicine · R01 · FY2023 · CA
Project 3: Inhibiting FAK to enhance immune checkpoint inhibitor therapy in LKB1-mutant lung adenocarcinoma
$540,114Adam I Marcus · Emory University · P01 · FY2024 · CA
HORMONAL CONTROL OF ADIPOSE GENE EXPRESSION
$539,946M Daniel Lane · Johns Hopkins University · R01 · FY2007 · DK
Overcoming Therapy Resistance in SCLC
$539,763Esra Akbay · Ut Southwestern Medical Center · R01 · FY2025 · CA
Preclinical-Clinical Trials Collaboration to effectively advance new combination therapies for malignant peripheral nerve sheath tumors
$539,600Karen M Cichowski · Brigham And Women'S Hospital · U01 · FY2025 · CA
Mechanisms of chromosome segregation, aneuploidy, and tumorigenesis
$539,556Don W. Cleveland · Ludwig Institute For Cancer Res Ltd · R35 · FY2017 · GM
Synthetic Lethal Targeting of SETD2 in Renal Cell Carcinoma
$539,540Keith D Robertson · Mayo Clinic Rochester · R01 · FY2025 · CA
Targeting tumor microenvironment by nanoimmunodrugs for glioma treatment
$539,533Alexander V Ljubimov · Cedars-Sinai Medical Center · R01 · FY2025 · CA
Interrogating the response of the tumor microenvironment to combination immunotherapy using a microfluidic platform
$539,424Albert Folch · University Of Washington · R01 · FY2025 · CA
PAG is a novel target in immunotherapy
$539,081Adam Mor · Columbia University Health Sciences · R01 · FY2024 · AI
Systems analysis of mechanisms driving response to immunotherapy in clear cell cancers
$539,080Andrew J. Gentles · Stanford University · U01 · FY2022 · CA
Mechanisms of immunosuppression in the development and progression of renal disease in Tuberous Sclerosis Complex
$539,046Elizabeth P Henske · Brigham And Women'S Hospital · R01 · FY2023 · DK
(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition
$538,983Justin M Balko · Vanderbilt University Medical Center · R01 · FY2019 · CA
Intravesical Immunotherapy of Spontaneous Canine Invasive Urothelial Carcinoma
$538,904David Zaharoff · North Carolina State University Raleigh · U01 · FY2022 · CA